EW - Edwards Lifesciences Corporation
NYSE
->
Healthcare
->
Medical Devices
Irvine,
United States
Type: Equity
EW price evolution
EW
| (in millions $) | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1144 | $1410.1 | $1042.6 | $872.5 |
| Short term investments | $500.5 | $453.8 | $466.7 | $381.7 |
| Net receivables | $836.9 | $802.1 | $816.9 | $779.3 |
| Inventory | $1168.2 | $1032.4 | $980.2 | $914.3 |
| Total current assets | $4035.7 | $4067.5 | $3647 | $3257.2 |
| Long term investments | $583.9 | $704.6 | $856.2 | $1066.7 |
| Property, plant & equipment | $1843.4 | $1772.2 | $1747.1 | $1734.5 |
| Goodwill & intangible assets | $1681.9 | $1727.2 | $1730.9 | $1755.2 |
| Total noncurrent assets | $5327.5 | $5303.3 | $5357 | $5394 |
| Total investments | $1084.4 | $1158.4 | $1322.9 | $1448.4 |
| Total assets | $9363.2 | $9370.8 | $9004 | $8651.2 |
| Current liabilities | ||||
| Accounts payable | $1170.5 | $1214.6 | $1132.9 | $1056.9 |
| Deferred revenue | ||||
| Short long term debt | $24.9 | $24.3 | $24.3 | $25.1 |
| Total current liabilities | $1195.4 | $1238.9 | $1157.2 | $1082 |
| Long term debt | $670 | $666.8 | $660.2 | $662.7 |
| Total noncurrent liabilities | $1448.4 | $1404.8 | $1400.3 | $1507.2 |
| Total debt | $694.9 | $691.1 | $684.5 | $687.8 |
| Total liabilities | $2643.8 | $2643.7 | $2557.5 | $2589.2 |
| Shareholders' equity | ||||
| Retained earnings | $8992.4 | $8622.5 | $8237.6 | $7930.5 |
| Other shareholder equity | -$242.8 | -$250.1 | -$255.5 | -$255.4 |
| Total shareholder equity | $6650 | $6657.5 | $6375.7 | $5978 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1144 | $769 | $862.8 | $1183.2 |
| Short term investments | $500.5 | $446.3 | $604 | $219.4 |
| Net receivables | $836.9 | $699.1 | $664.9 | $602.8 |
| Inventory | $1168.2 | $875.5 | $726.7 | $802.3 |
| Total current assets | $4035.7 | $3095.8 | $3180.7 | $3091 |
| Long term investments | $583.9 | $1239 | $1834.2 | $801.6 |
| Property, plant & equipment | $1843.4 | $1725.1 | $1638.7 | $1489.4 |
| Goodwill & intangible assets | $1681.9 | $1449.5 | $1491.5 | $1504.6 |
| Total noncurrent assets | $5327.5 | $5196.7 | $5321.9 | $4146.1 |
| Total investments | $1084.4 | $1685.3 | $2438.2 | $1021 |
| Total assets | $9363.2 | $8292.5 | $8502.6 | $7237.1 |
| Current liabilities | ||||
| Accounts payable | $1170.5 | $996.9 | $1006.8 | $866.7 |
| Deferred revenue | ||||
| Short long term debt | $24.9 | $25.5 | $25.5 | $27.2 |
| Total current liabilities | $1195.4 | $1022.4 | $1032.3 | $893.9 |
| Long term debt | $670 | $596.3 | $664.8 | $667.7 |
| Total noncurrent liabilities | $1448.4 | $1463.4 | $1634.4 | $1768.9 |
| Total debt | $694.9 | $691.3 | $690.3 | $694.9 |
| Total liabilities | $2643.8 | $2485.8 | $2666.7 | $2662.8 |
| Shareholders' equity | ||||
| Retained earnings | $8992.4 | $7590 | $6068.1 | $4565 |
| Other shareholder equity | -$242.8 | -$254.9 | -$157.7 | -$161.1 |
| Total shareholder equity | $6650 | $5806.7 | $5835.9 | $4574.3 |
| (in millions $) | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1480.9 | $1530.2 | $1459.6 | |
| Cost of revenue | $350.4 | $343 | $329.5 | |
| Gross Profit | $1130.5 | $1187.2 | $1130.1 | |
| Operating activities | ||||
| Research & development | $270.3 | $270.3 | $261.2 | |
| Selling, general & administrative | $439.6 | $468.7 | $436.3 | |
| Total operating expenses | $712.1 | $886.9 | $741 | |
| Operating income | $418.4 | $300.3 | $389.1 | |
| Income from continuing operations | ||||
| EBIT | $440.5 | $340.1 | $398.6 | |
| Income tax expense | $55.6 | $33 | $58.1 | |
| Interest expense | ||||
| Net income | ||||
| Net income | $384.9 | $307.1 | $340.5 | |
| Income (for common shares) | $384.9 | $307.1 | $340.5 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Jan 2022 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $6004.8 | $5382.4 | $4386.3 | |
| Cost of revenue | $1379.8 | $1080.4 | $1080.6 | |
| Gross Profit | $4625 | $4302 | $3305.7 | |
| Operating activities | ||||
| Research & development | $1071.8 | $945.2 | $760.7 | |
| Selling, general & administrative | $1824.6 | $1567.6 | $1228.4 | |
| Total operating expenses | $3117.1 | $2589.3 | $2394.5 | |
| Operating income | $1507.9 | $1712.7 | $911.2 | |
| Income from continuing operations | ||||
| EBIT | $1618.7 | $1786.6 | $932.5 | |
| Income tax expense | $198.7 | $245.5 | $93.3 | |
| Interest expense | $17.6 | $19.2 | $15.8 | |
| Net income | ||||
| Net income | $1402.4 | $1521.9 | $823.4 | |
| Income (for common shares) | $1402.4 | $1521.9 | $823.4 | |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | $369.9 | $384.9 | $307.1 | $340.5 |
| Operating activities | ||||
| Depreciation | $44.2 | $43.9 | $43 | $42 |
| Business acquisitions & disposals | $31 | -$156.2 | ||
| Stock-based compensation | $30.5 | $32.6 | $37.4 | $38.9 |
| Total cash flows from operations | $136.6 | $411.5 | $33.6 | $314.1 |
| Investing activities | ||||
| Capital expenditures | -$88.3 | -$55.3 | -$47.9 | -$61.5 |
| Investments | $78.8 | $145.8 | $120 | $233.2 |
| Total cash flows from investing | $14.1 | $89 | $70.2 | $0.5 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$415.2 | -$140.4 | $53.3 | -$207.4 |
| Net borrowings | -$0.3 | |||
| Total cash flows from financing | -$413.2 | -$143.3 | $52.1 | -$206.6 |
| Effect of exchange rate | -$3.4 | $9.2 | $15.2 | -$4.2 |
| Change in cash and equivalents | -$265.9 | $366.4 | $171.1 | $103.8 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $1402.4 | $1521.9 | $1503.1 | $823.4 |
| Operating activities | ||||
| Depreciation | $173.1 | $166.8 | $163.3 | $135.4 |
| Business acquisitions & disposals | -$125.2 | -$109.6 | -$13.1 | -$10 |
| Stock-based compensation | $139.4 | $126.8 | $109.3 | $92.6 |
| Total cash flows from operations | $895.8 | $1218.2 | $1732.1 | $1054.3 |
| Investing activities | ||||
| Capital expenditures | -$253 | -$244.6 | -$325.8 | -$407 |
| Investments | $577.8 | $655.5 | -$1335.2 | -$101.7 |
| Total cash flows from investing | $173.8 | $252.3 | -$1722.5 | -$531.1 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$709.7 | -$1580.7 | -$354.2 | -$484.9 |
| Net borrowings | -$0.3 | -$0.2 | -$1.8 | -$0.8 |
| Total cash flows from financing | -$711 | -$1584.5 | -$356.3 | -$486.9 |
| Effect of exchange rate | $16.8 | $19.2 | $13.9 | -$20.5 |
| Change in cash and equivalents | $375.4 | -$94.8 | -$332.8 | $15.8 |
News
Fundamentals
| Market cap | $52.27B |
|---|---|
| Enterprise value | $51.82B |
| Shares outstanding | 601.10M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 7.58 |
| Book/Share | 11.47 |
| Cash/Share | 1.90 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.40 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.38 |
| Quick ratio | 2.40 |